Evidence map›Paper›PMID 37309125›Full record

ArticleTechnology in cancer research & treatment

A Clinical Tool to Predict the Microvascular Invasion Risk in Patients with Hepatocellular Carcinoma.

Hui Sheng, Minjie Mao, Kewei Huang, Hailin Zheng, Wen Liu, Yongneng Liang

Abstract read
In one paragraph

Article in Technology in cancer research & treatment. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Hui ShengSun Yat-sen University Cancer Center, Guangzhou, China.
Minjie MaoSun Yat-sen University Cancer Center, Guangzhou, China.
Kewei HuangSun Yat-sen University Cancer Center, Guangzhou, China.
Hailin ZhengSun Yat-sen University Cancer Center, Guangzhou, China.
Wen LiuSun Yat-sen University Cancer Center, Guangzhou, China.
Yongneng LiangSun Yat-sen University Cancer Center, Guangzhou, China.ORCID 0000-0002-9059-9752

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMicrovascular invasion (MVI) plays an important role in tumor progression. The aim of this study is to establish and validate an effective hematological nomogram for MVI prediction in hepatocellular carcinoma (HCC).

methodsA retrospective study was performed in a primary cohort that includes 1306 patients clinicopathologically diagnosed with HCC, and a validation cohort contained 563 continuous patients. Univariate logistic regression was used to assess the association between variables included both clinicopathologic factors and coagulation parameters (prothrombin time, activated partial thromboplastin time, fibrinogen, and thrombin time [TT]) and MVI. Multiple logistic regression was used to construct a prediction nomogram. We tested the accuracy of the nomogram by discrimination and calibration, and then plotted decision curves to assess the benefits of the nomogram-assisted decisions in a clinical context.

resultsIn the two cohorts, patients without MVI had the longest overall survival (OS), compared the OS with MVI. The multivariate analysis indicated that age, sex, tumor node metastasis (TNM) stage, aspartate aminotransferase, alpha fetoprotein, C-reactive protein, and TT were identified as significant independent predictors of MVI of HCC patients. The Hosmer-Lemeshow test showed good point estimate associated

conclusionsA noninvasive and easy-to-use nomogram was established and may be used to predict preoperative MVI in HCC.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsC-Reactive ProteinFibrinogenHumansRetrospective StudiesC-Reactive ProteinFibrinogenbiomarkerhepatocellular carcinomamicrovascular invasionnomogramprediction

Identifiers

PMID37309125
PMCPMC10285600

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.